

# LIST OF SPECIALTY MEDICAL INJECTABLES WITH REIMBURSEMENT RESTRICTION

This list only applies to providers who are reimbursed based on a hospital fee schedule. It does not apply to physician fee schedules.

Updated June 2020

Per our Specialty Medical Injectables with Reimbursement Restriction guidelines, certain specialty medical injectables administered in the outpatient setting must be dispensed and their claims must be submitted by a specialty pharmacy with which Cigna has a reimbursement arrangement. We will not reimburse facilities that purchase these injectables directly from specialty pharmacies, manufacturers, or wholesalers.

**The Specialty Medical Injectables with Reimbursement Restriction list only applies to providers who bill Cigna using a hospital fee schedule; it does not apply to those who bill Cigna using their own physician fee schedules.** Additional information about these guidelines is available in the Cigna Reference Guide for physicians, hospitals, ancillaries, and other providers. To access this guide, log in to the Cigna for Health Care Professionals website ([CignaforHCP.com](http://CignaforHCP.com) > Resources > [Reference Guides](#)).

## Important: Please read

- The Specialty Medical Injectables with Reimbursement Restriction list has three categories:
  - Gene therapy injectables
  - Specialty medical injectables
  - Oncology injectables
- The Specialty Medical Injectables with Reimbursement Restriction list is subject to change without prior notice.

The following tables detail the affected drugs.

Gene Therapy Injectables <sup>1</sup>			
Healthcare Common Procedure Coding System (HCPCS) code(s)	Name	Contracted specialty pharmacy	Date prior authorization obtained (on or after)
J3398	LUXTURNA® (voretigene neparvovec-rzyl)	Accredo	May 1, 2018
C9399, J3490, J3590, J9999	ZOLGENSMA® (onasemnogene abeparvovec-xioi)	Accredo	May 24, 2019
C9399, J3490, J3590, J9999	ADSTILADRIN® (nadofaragene firadenovec)	Cigna contracted specialty pharmacy	Following U.S. Food and Drug Administration approval

1. These drugs, which Cigna has designated as gene therapy products, are included in the Cigna Gene Therapy Program. To access the list of designated gene therapy products, log in to [CignaforHCP.com](http://CignaforHCP.com) > Resources > Reimbursement Policies and Payment Policies > Precertification Policies > [Cigna Designated Gene Therapy Products Requiring Precertification](#).

Together, all the way.™



All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

Specialty Medical Injectables			
HCPSC code(s)	Name	Contracted specialty pharmacy	Date prior authorization obtained (on or after)
J2326	SPINRAZA® (nusinersen)	Accredo	May 1, 2018
J0567	BRINEURA® (cerliponase alfa)	Orsini Pharmaceutical Services	March 1, 2020
C9399, J3490	GIVLAARI® (givosiran)	Accredo, PANTHERx	March 1, 2020
J0180	Fabrazyme® (agalsidase beta) <sup>2</sup>	Accredo	September 1, 2020
J2840	KANUMA® (sebelipase alfa) <sup>2</sup>	Accredo	September 1, 2020
J0202	LEMTRADA® (alemtuzumab) <sup>2</sup>	Accredo	September 1, 2020
J0221	Lumizyme® (alglucosidase alfa) <sup>2</sup>	Accredo	September 1, 2020
J0222	ONPATTRO® (patisiran) <sup>2</sup>	Orsini Pharmaceutical Services	September 1, 2020
J1300	SOLIRIS® (eculizumab) <sup>2</sup>	Accredo	September 1, 2020
C9399, J3490, J3590, J9999	TEPEZZA™ (teprotumumab-trbw) <sup>2</sup>	Accredo	September 1, 2020
J1303	ULTOMIRIS® (ravulizumab-cwvz) <sup>2</sup>	Accredo	September 1, 2020
C9399, J3490, J3590, J9999	VYONDYS 53® (golodirsen) <sup>2</sup>	Orsini Pharmaceutical Services	September 1, 2020

2. Cigna may grant an exception to reimburse a one-time, or single, administration of a specialty medical injectable billed by a facility when a customer needs access to the injectable before it can be obtained from a specialty pharmacy with which Cigna has a reimbursement arrangement. The Specialty Medical Injectables with Reimbursement Restriction list only applies to providers who bill Cigna using a hospital fee schedule; it does not apply to those who bill Cigna using their own physician fee schedules.

Together, all the way.™



All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

Oncology Injectables <sup>3</sup>			
HCPSC code(s)	Name	Contracted specialty pharmacy	Date prior authorization obtained (on or after)
C9399, J3490, J3590, J9999	ENHERTU <sup>®</sup> (trastuzumab deruxtecan) <sup>4</sup>	Accredo	September 1, 2020
J9299	OPDIVO <sup>®</sup> (nivolumab) <sup>4</sup>	Accredo	September 1, 2020
J9228	YERVOY <sup>®</sup> (ipilimumab) <sup>4</sup>	Accredo	September 1, 2020

3. When prescribing oncology drugs for your patients with Cigna coverage, please request prior authorization, when it's needed, through eviCore healthcare. To access the full list of drugs requiring prior authorization, log in to [CignaforHCP.com](https://CignaforHCP.com) > Resources > Reimbursement Policies and Payment Policies > Precertification Policies > [Oncology Drugs Requiring Precertification through eviCore Healthcare](#).

4. Cigna may grant an exception to reimburse a one-time, or single, administration of an oncology injectable billed by a facility when a customer needs access to the injectable before it can be obtained from a specialty pharmacy with which Cigna has a reimbursement arrangement. The Specialty Medical Injectables with Reimbursement Restriction list only applies to providers who bill Cigna using a hospital fee schedule; it does not apply to those who bill Cigna using their own physician fee schedules.

Together, all the way.™



All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.